InvestorsObserver
Sign Up Login

RIGL Rigel Pharmaceuticals

$1.85 $0.00 (0.00%)
Add to Watchlist Compare
Overall

RIGL Stock Analysis Overview

What this means: InvestorsObserver gives Rigel Pharmaceuticals (RIGL) an overall rank of 48, which is below average. Rigel Pharmaceuticals is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 48 means that 52% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

RIGL Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

RIGL Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

RIGL Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

RIGL Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

RIGL Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

RIGL Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

RIGL Stock Analysis Overview

What this means: InvestorsObserver gives Rigel Pharmaceuticals (RIGL) an overall rank of 48, which is below average. Rigel Pharmaceuticals is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 48 means that 52% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full RIGL report

RIGL Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

RIGL Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

RIGL Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

RIGL Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

RIGL Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

RIGL Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Rigel Pharmaceuticals (RIGL) Analyst Forecast

RIGL Price, Volume, Earnings, and Dividend Date

  • Last Price $1.85
  • Previous Close $1.85
  • Change $0.00
  • Open $1.94
  • Volume 1,538,600
  • Avg. Volume (100-day) 1,839,508
  • Market Cap 318,296,614
  • Days Range 1.84 - 1.98
  • 52-week Range 1.8 - 4.62
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/01/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.909
  • PEG Ratio —

Rigel Pharmaceuticals (RIGL) Company Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (RIGL) Stock Chart

View Interactive RIGL chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Point Biopharma Global Inc (PNT) (PNT) $7.44
Catalyst Bio (CBIO) (CBIO) $1.34
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $22.20
Trevi Therapeutics Inc (TRVI) (TRVI) $2.20
SC Pharmaceuticals Inc (SCPH) (SCPH) $5.11
Concert Pharmaceutic (CNCE) (CNCE) $4.21
Veru Inc (VERU) (VERU) $12.21
Savara Inc (SVRA) (SVRA) $1.38
Mirum Pharmaceuticals Inc (MIRM) (MIRM) $25.26
Lyra Therapeutics Inc (LYRA) (LYRA) $6.00